<p>Revance Therapeutics, Inc.（纳斯达克股票代码：RVNC - 获取免费报告）的股价在周四的午盘交易中下跌了 3.5%。该公司的股价最低跌至 5.78 美元，最后交易价为 5.78 美元。约有 2,104,008 股在交易中换手，较平均每日成交量 2,847,570 股下降了 26%。该股上一个收盘价为 5.99 美元。</p>
<p>获取 <strong>Revance Therapeutics</strong> 的警报：</p>
<h2>分析师评级变动</h2>
<ul>
<li>华尔街看好 Botox 竞争对手 Revance，预计上涨 23%</li>
</ul>
<p>多位研究分析师对 RVNC 股票发表了意见。Guggenheim 在 8 月 12 日星期一的报告中重申了对 Revance Therapeutics 股票的 “中性” 评级。StockNews.com 在周日的研究报告中开始对 Revance Therapeutics 股票进行覆盖。他们为该公司发行了 “持有” 评级。William Blair 在 8 月 12 日星期一的研究报告中重申了对 Revance Therapeutics 股票的 “市场表现” 评级。HC Wainwright 在 8 月 13 日星期二的报告中将 Revance Therapeutics 股票的评级从 “强烈买入” 调低为 “持有”。最后，巴克莱在 9 月 13 日星期五的研究报告中重申了对 Revance Therapeutics 股票的 “等权重” 评级，并设定了 7.00 美元的价格目标（降低自 10.00 美元）。十位分析师对该股票进行了持有评级，一位对该股票进行了买入评级。根据 MarketBeat 的数据，该股目前的共识评级为 “持有”，平均目标价为 10.50 美元。</p>
<p><strong>查看我们对 Revance Therapeutics 的最新股票分析</strong></p>
<h2>Revance Therapeutics 股价下跌 2.3%</h2>
<p>该公司的市值为 6.1103 亿美元，市盈率为-1.65，贝塔系数为 1.00。该股的 50 天移动平均价为 5.24 美元，200 天移动平均价为 4.29 美元。</p>
<p>Revance Therapeutics（纳斯达克股票代码：RVNC - 获取免费报告）最近公布了其截至 8 月 8 日星期四的季度财报。这家生物制药公司在该季度报告中每股亏损 0.36 美元，超过了分析师预期的 0.48 美元，增加了 0.12 美元。该公司在该季度的营收为 6539 万美元，低于 6330 万美元的共识预期。该业务该季度的营收同比增长了 20.2%。在去年同期的同一季度，该公司每股亏损为 0.80 美元。</p>
<h2>对 Revance Therapeutics 的对冲基金看法</h2>
<p>对冲基金最近买卖了该公司的股票。Victory Capital Management Inc.在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 93,000 美元。查尔斯·施瓦布投资管理公司在第四季度增持了 Revance Therapeutics 的股份 2.1%。查尔斯·施瓦布投资管理公司现在拥有 677,364 股这家生物制药公司的股票，价值 595.4 万美元，在此期间增持了 13,826 股。Dynamic Technology Lab Private Ltd 在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 240,000 美元。Trexquant Investment LP 在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 578,000 美元。最后，Quest Partners LLC 在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 84,000 美元。机构投资者拥有该公司股票的 97.70%。</p>
<h2>Revance Therapeutics 公司简介（获取免费报告）</h2>
<p>Revance Therapeutics, Inc.是一家生物技术公司，致力于在美国和国际市场开发、生产和销售用于各种美容和治疗用途的神经调节剂。该公司的主要药物候选品是 DAXXIFY（达西布肉毒杆菌 A-lanm）注射液，用于治疗眉间纹和颈部肌张力障碍；已完成 II 期临床试验，用于治疗上半脸皱纹、中度或重度动态前额纹和中度或重度外眼角纹；并已完成 II 期临床试验，用于治疗成人上肢痉挛和跖腱炎。</p>
<h2>参见</h2>
<ul>
<li>我们比 Revance Therapeutics 更喜欢的五只股票</li>
<li>金叉股票：模式、示例和图表</li>
<li>Edgewise Therapeutics 飙升 50%：涨势背后的关键原因</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>联邦储备降息如何加速这 3 只 ETF 的增长</li>
<li>市值计算器：如何计算市值</li>
<li>微软股票：它准备在第四季度压倒性地击败</li>
</ul>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 对埃隆的战争升级...（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ0"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Revance Therapeutics 股票？</h2>
<p>在考虑 Revance Therapeutics 之前，您可能会想听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 Revance Therapeutics 并不在名单上。</p>
<p>尽管 Revance Therapeutics 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RVNC

<p>Revance Therapeutics（NASDAQ: RVNC）股价在午间交易中下跌了 3.5%，收盘价为 0.78 美元。交易量比平均水平下降了 26%。分析师对该股票的评级褒贬不一，其中十家持有评级，一家买入评级。该公司报告的季度每股收益为-0.36 美元，超出预期，营收为 1.239 亿美元，同比增长 20.2%。机构投资者持有该股票的比例为 97.70%。Revance 专注于开发神经调节剂，包括其主力候选药物 DAXXIFY，用于美容和治疗用途</p>

<p>Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report)'s share price dropped 3.5% during mid-day trading on Thursday . The company traded as low as $5.78 and last traded at $5.78. Approximately 2,104,008 shares traded hands during trading, a decline of 26% from the average daily volume of 2,847,570 shares. The stock had previously closed at $5.99.</p>
<div class="lb-trans"><p>Revance Therapeutics, Inc.（纳斯达克股票代码：RVNC - 获取免费报告）的股价在周四的午盘交易中下跌了 3.5%。该公司的股价最低跌至 5.78 美元，最后交易价为 5.78 美元。约有 2,104,008 股在交易中换手，较平均每日成交量 2,847,570 股下降了 26%。该股上一个收盘价为 5.99 美元。</p>
</div><p>Get <strong>Revance Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Revance Therapeutics</strong> 的警报：</p>
</div><h2>Analyst Ratings Changes</h2>
<ul>
<li>Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor</li>
</ul>
<div class="lb-trans"><h2>分析师评级变动</h2>
<ul>
<li>华尔街看好 Botox 竞争对手 Revance，预计上涨 23%</li>
</ul>
</div><p>Several research analysts have weighed in on RVNC shares. Guggenheim restated a &#34;neutral&#34; rating on shares of Revance Therapeutics in a report on Monday, August 12th. StockNews.com initiated coverage on shares of Revance Therapeutics in a research note on Sunday. They issued a &#34;hold&#34; rating for the company. William Blair reiterated a &#34;market perform&#34; rating on shares of Revance Therapeutics in a research report on Monday, August 12th. HC Wainwright lowered shares of Revance Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, August 13th. Finally, Barclays reissued an &#34;equal weight&#34; rating and set a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Ten analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $10.50.</p>
<div class="lb-trans"><p>多位研究分析师对 RVNC 股票发表了意见。Guggenheim 在 8 月 12 日星期一的报告中重申了对 Revance Therapeutics 股票的 “中性” 评级。StockNews.com 在周日的研究报告中开始对 Revance Therapeutics 股票进行覆盖。他们为该公司发行了 “持有” 评级。William Blair 在 8 月 12 日星期一的研究报告中重申了对 Revance Therapeutics 股票的 “市场表现” 评级。HC Wainwright 在 8 月 13 日星期二的报告中将 Revance Therapeutics 股票的评级从 “强烈买入” 调低为 “持有”。最后，巴克莱在 9 月 13 日星期五的研究报告中重申了对 Revance Therapeutics 股票的 “等权重” 评级，并设定了 7.00 美元的价格目标（降低自 10.00 美元）。十位分析师对该股票进行了持有评级，一位对该股票进行了买入评级。根据 MarketBeat 的数据，该股目前的共识评级为 “持有”，平均目标价为 10.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Revance Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Revance Therapeutics 的最新股票分析</strong></p>
</div><h2>Revance Therapeutics Trading Down 2.3 %</h2>
<div class="lb-trans"><h2>Revance Therapeutics 股价下跌 2.3%</h2>
</div><p>The company has a market cap of $611.03 million, a P/E ratio of -1.65 and a beta of 1.00. The stock's 50 day moving average is $5.24 and its 200-day moving average is $4.29.</p>
<div class="lb-trans"><p>该公司的市值为 6.1103 亿美元，市盈率为-1.65，贝塔系数为 1.00。该股的 50 天移动平均价为 5.24 美元，200 天移动平均价为 4.29 美元。</p>
</div><p>Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. The business's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.80) EPS.</p>
<div class="lb-trans"><p>Revance Therapeutics（纳斯达克股票代码：RVNC - 获取免费报告）最近公布了其截至 8 月 8 日星期四的季度财报。这家生物制药公司在该季度报告中每股亏损 0.36 美元，超过了分析师预期的 0.48 美元，增加了 0.12 美元。该公司在该季度的营收为 6539 万美元，低于 6330 万美元的共识预期。该业务该季度的营收同比增长了 20.2%。在去年同期的同一季度，该公司每股亏损为 0.80 美元。</p>
</div><h2>Hedge Funds Weigh In On Revance Therapeutics</h2>
<div class="lb-trans"><h2>对 Revance Therapeutics 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in Revance Therapeutics during the 4th quarter valued at about $93,000. Charles Schwab Investment Management Inc. lifted its stake in Revance Therapeutics by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,364 shares of the biopharmaceutical company's stock valued at $5,954,000 after acquiring an additional 13,826 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Revance Therapeutics during the 4th quarter valued at about $240,000. Trexquant Investment LP bought a new position in Revance Therapeutics during the 4th quarter valued at about $578,000. Finally, Quest Partners LLC bought a new position in Revance Therapeutics during the 4th quarter valued at about $84,000. Institutional investors own 97.70% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近买卖了该公司的股票。Victory Capital Management Inc.在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 93,000 美元。查尔斯·施瓦布投资管理公司在第四季度增持了 Revance Therapeutics 的股份 2.1%。查尔斯·施瓦布投资管理公司现在拥有 677,364 股这家生物制药公司的股票，价值 595.4 万美元，在此期间增持了 13,826 股。Dynamic Technology Lab Private Ltd 在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 240,000 美元。Trexquant Investment LP 在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 578,000 美元。最后，Quest Partners LLC 在第四季度新建了一份 Revance Therapeutics 的头寸，价值约为 84,000 美元。机构投资者拥有该公司股票的 97.70%。</p>
</div><h2>Revance Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Revance Therapeutics 公司简介（获取免费报告）</h2>
</div><p>Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.</p>
<div class="lb-trans"><p>Revance Therapeutics, Inc.是一家生物技术公司，致力于在美国和国际市场开发、生产和销售用于各种美容和治疗用途的神经调节剂。该公司的主要药物候选品是 DAXXIFY（达西布肉毒杆菌 A-lanm）注射液，用于治疗眉间纹和颈部肌张力障碍；已完成 II 期临床试验，用于治疗上半脸皱纹、中度或重度动态前额纹和中度或重度外眼角纹；并已完成 II 期临床试验，用于治疗成人上肢痉挛和跖腱炎。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Revance Therapeutics</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>How the Fed’s Rate Cut Could Supercharge These 3 ETFs</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Microsoft Stock: 3 Reasons It’s Ready to Crush Q4</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们比 Revance Therapeutics 更喜欢的五只股票</li>
<li>金叉股票：模式、示例和图表</li>
<li>Edgewise Therapeutics 飙升 50%：涨势背后的关键原因</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>联邦储备降息如何加速这 3 只 ETF 的增长</li>
<li>市值计算器：如何计算市值</li>
<li>微软股票：它准备在第四季度压倒性地击败</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ War on Elon Escalates… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 对埃隆的战争升级...（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjQ0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9244&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Revance Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Revance Therapeutics 股票？</h2>
</div><p>Before you consider Revance Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Revance Therapeutics 之前，您可能会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revance Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 Revance Therapeutics 并不在名单上。</p>
</div><p>While Revance Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Revance Therapeutics 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Revance Therapeutics（纳斯达克代码：RVNC）股价下跌 3.5%